Any current/future capex/capital investment/strategic investment?

FY 2026 capex was INR 165 crores, split evenly between India, Philippines, and a bit in Uzbekistan. Capex per bed: India ~ INR 10-11 lakhs, Philippines ~ INR 40-45 lakhs. Payback periods: India ~3.5-4 years, Philippines ~1-1.5 years. Planned clinic additions: India 40-50 new clinics/year, Philippines 12-15 new clinics/year (excluding large PPPs or big acquisitions). Future investments include expanding Philippines support areas like supply chain management and business development. Repair and maintenance expenses now flow through operating expenses due to accounting changes. Exploring Public-P

Future growth expectations in sales/revenue/volumes?

FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT). Treatment volumes increased 16.6% YoY; active guests up 11.8%. RPT rose 13.3%, boosted by international market mix increase (32% to 42%), favorable forex, and a 58% price hike in the Philippines. India plans to add 40-50 new clinics annually; Philippines targeting 12-15 clinics/year. Clinic expansions focus on treatment volume growth, as per-machine capacity is fixed; new clinics needed for volume increase. Price hikes are infrequent and stepwis

Future growth expectations in earnings/operating earnings/profits/EPS?

NephroPlus expects a medium-term CAGR growth of 15% to 20% over the next 3-4 years driven by three growth levers: same-clinic growth, new clinic rollout in existing geographies, and new geography/large acquisitions/PPPs. Revenue growth in FY '26 was strong at 32.2%, with patient volumes and treatment sessions expanding steadily. Adjusted EBITDA grew 37.6% in FY '26 with margin expansion from 22.8% to 23.8%, indicating improving operational efficiency. Adjusted PAT grew 74.6% in FY '26 with margin improvement from 9.7% to 12.8%. Profitability and ROCE are expected to improve as the company scal

IN US

Sale is live|00:00:00left today

Nephrocare Health Services LtdQ1 FY26Healthcare Services

Nephrocare Health Services Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹684P/E: 82.2Market Cap: ₹6.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT).
→Treatment volumes increased 16.6% YoY; active guests up 11.8%.
→RPT rose 13.3%, boosted by international market mix increase (32% to 42%), favorable forex, and a 58% price hike in the Philippines.
→India plans to add 40-50 new clinics annually; Philippines targeting 12-15 clinics/year.
→Clinic expansions focus on treatment volume growth, as per-machine capacity is fixed; new clinics needed for volume increase.
→Price hikes are infrequent and stepwise; no significant increases expected next year; growth primarily volume-driven.
→Foreign expansion (Philippines, Uzbekistan) projected to continue being profitable and fuel higher RPT.
→Saudi Arabia market is under investment phase; growth visibility expected in next few quarters following tender outcomes.

Margin guidance

Category 3

→NephroPlus expects a medium-term CAGR growth of 15% to 20% over the next 3-4 years driven by three growth levers: same-clinic growth, new clinic rollout in existing geographies, and new geography/large acquisitions/PPPs.
→Revenue growth in FY '26 was strong at 32.2%, with patient volumes and treatment sessions expanding steadily.
→Adjusted EBITDA grew 37.6% in FY '26 with margin expansion from 22.8% to 23.8%, indicating improving operational efficiency.
→Adjusted PAT grew 74.6% in FY '26 with margin improvement from 9.7% to 12.8%.
→Profitability and ROCE are expected to improve as the company scales its platform internationally with higher price points and operational leverage.
→No near-term large price hikes expected; revenue per treatment growth will mainly come from expanding higher-priced international markets.
→Capital allocation will remain disciplined, focusing on ROCE-accretive expansions.

3 more insights locked — sign up free to unlock

Fundraise plans

The document does not explicitly mention any current or future plans for fundraising through debt or equity. Key relevant points include: - The company is currently in an investment phase in certain geographies like Saudi Arabia, indicating ongoing capital deployment. - Capex guidance includes organic clinic expansions in India (~40-50 clinics) and Philippines (12-15 clinics) without mentioning planned fundraising. - No specific reference to equity issuance or debt raising activities during the Q&A or management commentary. - The focus appears on operational and clinic network growth funded through internal accruals or existing financial resources. - The company remains cautious with investments and tender participations, awaiting clearer visibility before scaling. In summary, no clear disclosures or guidance on new debt or equity fundraising are provided in the discussions on page 24 or adjacent pages.

Order book

The document does not provide explicit details on the current or expected order book or pending orders for Nephrocare Health Services Limited. However, relevant insights include: - Saudi Arabia tender market: The company is in the investment phase; a new tender was released about a month ago and is at the Expression of Interest (EOI) stage. Final visibility on clinic count or order conversion expected in a few quarters. - PPP contracts: For example, the Uttarakhand PPP contract is under renewal with tendering ongoing; resolution expected in 2-4 months, though delays possible. - Growth levers: Expansion includes new clinics (40-50 in India; 12-15 in Philippines), excluding large M&A or PPP contracts which are unpredictable and not currently factored into AOP. - No explicit quantified order book or backlog figures disclosed.

Capex plans

Yes

→FY 2026 capex was INR 165 crores, split evenly between India, Philippines, and a bit in Uzbekistan.
→Capex per bed: India ~ INR 10-11 lakhs, Philippines ~ INR 40-45 lakhs.
→Payback periods: India ~3.5-4 years, Philippines ~1-1.5 years.
→Planned clinic additions: India 40-50 new clinics/year, Philippines 12-15 new clinics/year (excluding large PPPs or big acquisitions).
→Future investments include expanding Philippines support areas like supply chain management and business development.
→Repair and maintenance expenses now flow through operating expenses due to accounting changes.
→Exploring Public-Private Partnership (PPP) models in Philippines and India as a strategic growth lever.
→Investing in IT and international business development to deepen presence and improve operational efficiency.
→Saudi Arabia JV in investment phase; clinic launch planned to showcase clinical excellence.

How does Nephrocare Health Services Ltd rank vs peers in Healthcare Services?

Pro feature

1Nephrocare Health Services Ltd

Rev 2Mar 3

See full Healthcare Services sector rankings

Want more stocks like Nephrocare Health Services Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio